Online inquiry

IVTScrip™ mRNA-Anti-IL13&IL4, SAR156597(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14539MR)

This product GTTS-WQ14539MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IL13&IL4 gene. The antibody can be applied in Idiopathic pulmonary fibrosis research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_001354991.2; NM_000589.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3596; 3565
UniProt ID P35225; P05112
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL13&IL4, SAR156597(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ14539MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ2074MR IVTScrip™ mRNA-Anti-Canlupfam PDCD1, AH-PD1(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AH-PD1
GTTS-WQ8499MR IVTScrip™ mRNA-Anti-ITGAL, hu1124(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA hu1124
GTTS-WQ1332MR IVTScrip™ mRNA-Anti-EGFR, ABT-806(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ABT-806
GTTS-WQ6187MR IVTScrip™ mRNA-Anti-CD40, CP-870893(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CP-870893
GTTS-WQ11075MR IVTScrip™ mRNA-Anti-CSF1, MCS-110(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MCS-110
GTTS-WQ6857MR IVTScrip™ mRNA-Anti-KLKB1, DX-2930(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA DX-2930
GTTS-WQ4818MR IVTScrip™ mRNA-Anti-CD4, BT-061(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BT-061
GTTS-WQ4265MR IVTScrip™ mRNA-Anti-LINGO1, BIIB-033(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BIIB-033
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW